Citius Pharmaceuticals, Inc.

191 articles about Citius Pharmaceuticals, Inc.

• Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023

  9/18/2023

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) has rescheduled its participation in Sidoti's Small-Cap Virtual Conference to November 2023 due to funeral services for the late Howard Safir, a long-time member of the Citius Board.

• Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir

  9/13/2023

  Citius Pharmaceuticals, Inc. mourns the loss of longtime board member, Howard Safir, who passed away on Monday.

• Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™

  9/8/2023

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has received additional guidance from the U.S. Food and Drug Administration (FDA) regarding the planned resubmission of the Company's Biologics License Application (BLA) for LYMPHIR™ (denileukin diftitox).

• Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023

  9/6/2023

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two investor conferences in September 2023.

• Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update

  8/14/2023

  Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products reported business and financial results for the fiscal third quarter ended June 30, 2023.

• Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial

  8/10/2023

  Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, announced that it has reached an important milestone in its clinical trial for Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.

• Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

  7/29/2023

  Citius Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the Company's Biologics License Application seeking approval for denileukin diftitox, an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy.

• 

  FDA Action Alert: Verrica, Citius and Daiichi Sankyo

  7/17/2023

  After beginning July with a splash in the Alzheimer's space, the FDA is expected to make three decisions during the next two weeks; two for cancer and one for a viral skin disease.

• Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes

  6/26/2023

  Citius Pharmaceuticals, Inc. today announced that it is set to be added to the broad-market Russell 3000 ® Index and the small-cap Russell 2000 ® Index at the conclusion of the annual reconstitution of Russell US Indexes, effective at the opening of the U.S. equity markets on June 26, 2023.

• Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

  6/20/2023

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR) today announced results from the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoid symptoms. 

• Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023

  6/13/2023

  Citius Pharmaceuticals, Inc. announced that Chairman and CEO Leonard Mazur will participate in a fireside chat with Senior Biotech Research Analyst, Michael Okunewitch, at Maxim Group's Virtual Healthcare Conference on June 21, 2023.

• Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update

  5/12/2023

  Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products reported business and financial results for the fiscal second quarter ended March 31, 2023.

• Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

  5/8/2023

  Citius Pharmaceuticals Inc. announced the closing of its previously announced registered direct offering with certain healthcare-focused and institutional investors for the purchase of an aggregate of 12,500,001 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,500,001 shares of its common stock, at a purchase price of $1.20 per share and accompanying warrant.

• Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

  5/4/2023

  Citius Pharmaceuticals Inc. today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 12,500,001 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,500,001 shares of its common stock.

• Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date

  4/24/2023

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it has advanced its clinical trial for Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.

• Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

  4/3/2023

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids.

• Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company

  3/30/2023

  Citius Pharmaceuticals, Inc. announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK.

• Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank

  3/13/2023

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB.

• Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference

  3/8/2023

  Citius Pharmaceuticals, Inc. today announced its participation in the 35th Annual Roth Conference being held March 12-14, 2023 in Dana Point, California.

• Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update

  2/10/2023

  Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products reported business and financial results for the fiscal first quarter ended December 31, 2022.